Cyclic A-beta Peptide Immunogen for Selective Oligomer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies fail to selectively target amyloid-beta oligomers, which are elusive due to their conformational plasticity and low concentration, making them challenging for therapeutic intervention in Alzheimer's disease.
Innovation Solution
Development of cyclic compounds comprising specific A-beta peptide sequences like HHQK, coupled with linkers, which are designed to expose distinct conformational epitopes accessible only in oligomeric forms, enabling selective antibody binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear A-beta peptides are used as immunogens, then antibodies can be generated, but they fail to selectively bind oligomers due to conformational plasticity
Solution Approach 1:
The patent changes the conformational parameters of the immunogen from linear to cyclic structure. This parameter change creates a more rigid, defined three-dimensional structure that can selectively recognize and bind to the specific conformational epitopes exposed on A-beta oligomers, overcoming the selectivity problem caused by oligomeric conformational plasticity
Solution Approach 2:
The patent employs cyclic peptides with curved or three-dimensional structures instead of linear peptides. This curvature creates a stable spatial configuration that can accommodate and selectively bind to the conformational epitopes on oligomers, providing reliable selectivity despite the target's conformational variability
2Reliability
If antibodies target A-beta oligomers, then therapeutic effect can be achieved, but oligomers are elusive due to low concentration
Solution Approach 1:
The patent uses cyclic peptides as immunogens to pre-program the antibody's binding specificity before exposure to the target. This preliminary action of immunization with conformationally-defined cyclic peptides ensures that the resulting antibodies are pre-equipped to recognize and bind tightly to oligomeric structures, enabling effective targeting even at low concentrations
Solution Approach 2:
The patent creates cyclic peptide copies or mimics of the conformational epitopes found on A-beta oligomers. These cyclic peptide copies serve as surrogate targets during immunization, allowing the generation of antibodies that will specifically recognize the actual oligomeric structures in the target system, thereby achieving therapeutic effectiveness despite low oligomer concentrations
3Reliability
If cyclic compounds with linkers are used, then selective binding to oligomers is achieved, but device complexity increases
Solution Approach 1:
The patent divides the cyclic compound into functional segments: the core cyclic peptide structure containing the conformational epitope, and the attached linker moiety. This segmentation allows the cyclic peptide portion to maintain simple, defined structure for selective binding, while the linker portion handles the complexity of conjugation and orientation, thereby achieving selectivity with manageable structural complexity
Data Source
AI summary
The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.